Sermorelin

01 · What it is

Sermorelin is GRF(1-29), a synthetic peptide whose amino acid composition is identical to the N-terminal 29 residues of hypothalamic growth hormone-releasing hormone, GHRH(1-44) ³. Those 29 residues carry the full biological activity of the parent hormone: everything from residue 30 onward can be removed without abolishing receptor activation. It acts on the growth hormone-releasing hormone receptor of anterior pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone ¹.

Its regulatory history is unlike anything else in this roadmap, and it is the reason to read this guide. Sermorelin acetate was approved twice by the US Food and Drug Administration: in the early 1990s as a diagnostic agent for adult growth hormone deficiency, given as a single 1 µg/kg intravenous injection under the name Geref Diagnostic; and in the late 1990s as a treatment for short stature associated with paediatric growth hormone deficiency, at 30 µg/kg/day subcutaneously, under the name Geref Pediatric, NDA 020443 ¹⁷. It was withdrawn from the US market in 2008 — not for safety, and not for lack of efficacy, but because the manufacturer discontinued it as a business decision when the active ingredient ceased to be produced ¹⁷.

That distinction matters for how the evidence should be read. A compound withdrawn for safety carries a warning. A compound withdrawn because nobody was making the raw material carries no scientific verdict at all — its efficacy data stand exactly as they did in 1999.

What did not stand is the research. Sermorelin’s clinical literature is largely a product of the 1980s and 1990s; almost every modern paper carrying its name is analytical chemistry written to detect it in urine ^{6,8,9,10,11,12} or a review of unsupervised use ^5,14,15,16.

02 · Evidence at a glance

Evidence grade

Approved Pharma — see the note below

Structure

GRF(1-29); identical to the N-terminal 29 residues of GHRH(1-44) ³

Molecular target

Growth hormone-releasing hormone receptor, anterior pituitary ¹

First US approval

Early 1990s, diagnostic agent for adult growth hormone deficiency, 1 µg/kg IV ¹⁷

Second US approval

Late 1990s, paediatric growth hormone deficiency, 30 µg/kg/day SC, NDA 020443 ¹⁷

Current US authorisation

None. Withdrawn from marketing in 2008 ¹⁷

Reason for withdrawal

Business decision; active ingredient no longer manufactured. Not safety, not efficacy ¹⁷

Diagnostic performance

Response to 1 µg/kg IV described as a rapid and relatively specific test for growth hormone deficiency ²

Modern clinical research

Minimal. Recent literature is dominated by doping-control analytical chemistry

Human pharmacokinetics

Characterised through the approval pathway; degradation profile studied further for anti-doping ^6,9

Grading note. The rubric defines Approved Pharma as holding marketing authorisation in at least one jurisdiction, in the present tense, and sermorelin holds none today. It is graded Approved Pharma here because it twice cleared an approval standard on its own evidence, and the reason it no longer holds authorisation is commercial rather than scientific. The alternative reading — Early Clinical, on the basis that the current authorisation is what counts — is defensible, and the evidence beneath either grade is the same.

03 · Mechanism of action

GHRH receptor agonism at the minimum active sequence

Sermorelin is the shortest fully active fragment of GHRH. GHRH(1-44) is the native hypothalamic hormone; GRF(1-29) retains its receptor-binding and activating capacity, which is why sermorelin has served as the reference GHRH agonist in endocrine physiology for four decades ^1,3. Both intravenous and subcutaneous administration specifically stimulate growth hormone secretion from the anterior pituitary ². “Specifically” is the operative word: the response is mediated through the pituitary rather than by supplying growth hormone directly, which is what makes the compound useful as a diagnostic probe.

Why that makes it a test rather than a treatment

A diagnostic agent needs a predictable, interpretable response in a healthy axis and an absent or blunted one in a diseased axis. Sermorelin’s approved diagnostic use rests on exactly that: a single 1 µg/kg intravenous dose produces a growth hormone response that distinguishes pituitary-level deficiency from hypothalamic-level deficiency, because a pituitary that cannot respond to direct GHRH stimulation is a pituitary that is itself impaired ^2,17. This is the clearest example in the roadmap of a peptide whose value lies in what its response reveals rather than in a therapeutic effect.

Degradation, and the reason the molecule is short-acting

Unmodified GRF(1-29) is cleaved rapidly at the Ala2 position by dipeptidyl peptidase-4, giving a circulating half-life measured in minutes. In vitro enzymatic and serum stability work conducted for doping control has characterised the degradation profile in detail, identifying the fragments sermorelin(1-11), sermorelin(13-20) and sermorelin(22-29) among the products ⁹, and further metabolite mapping has been performed in urine matrices ^6,12.

The compounds later marketed as CJC-1295 exist because of this degradation problem — they are GRF(1-29) with the cleavage site protected.

Pulsatility and the physiological argument

Because sermorelin acts upstream of the pituitary, growth hormone release remains subject to somatostatin restraint and negative feedback, and the resulting secretion is pulsatile rather than continuous. This is the class-level argument for GHRH analogues over exogenous growth hormone, and it was made explicitly for sermorelin in adult growth hormone insufficiency ⁴. The argument is physiologically sound. What it lacks is a trial demonstrating that the preserved pulsatility produces a better clinical outcome than the alternative, in any population.

An unexpected recent finding

A 2021 high-throughput drug screening study in recurrent glioma reported that patients with recurrent disease were most sensitive to sermorelin among the compounds screened, with the signal strongest in high-grade, IDH-wildtype, 1p/19q non-codeleted tumours ⁷.

This is a computational screening result in tumour datasets, not a treatment study, and it should not be read as evidence of benefit. It is included because it is the only substantive new biological hypothesis attached to this compound in twenty years.

04 · Key research findings

Diagnosis of growth hormone deficiency — the approved use and the best evidence. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary, and the response to 1 µg/kg intravenously constitutes a rapid and relatively specific test for growth hormone deficiency ². This use carried an FDA approval in the early 1990s ¹⁷.

The diagnostic literature is the strongest part of this compound’s file, and it is the part nobody discusses.

Paediatric growth hormone deficiency — the therapeutic approval. Geref Pediatric was approved in the late 1990s for short stature associated with growth hormone deficiency in children, at 30 µg/kg/day subcutaneously, under NDA 020443 ¹⁷. The supporting evidence was reviewed contemporaneously in the drug-development literature ².

An approval for a growth outcome in children is a demanding standard: the endpoint is height velocity over years, measured against comparators, in a population where the deficiency is documented.

Adult growth hormone insufficiency — proposed, not established. Commentary in the ageing literature proposed sermorelin as a better approach to adult-onset growth hormone insufficiency than exogenous growth hormone, on the pulsatility argument ⁴.

A proposal in a commentary is a hypothesis. No adult efficacy trial followed it into the indexed literature.

Modern use, and what the literature actually says about it. Sermorelin appears in reviews of growth hormone secretagogue use for body composition in hypogonadal men alongside GHRP-2, GHRP-6, ibutamoren and ipamorelin ⁵, in a 2026 review of performance-enhancing peptides modulating the GH–IGF1 axis that treats it as one of the agents encountered in online self-administration protocols ¹⁶, and in critical reviews of peptide use in sport and bodybuilding ¹⁵. Every one of these reviews describes a pattern of use, not a body of efficacy evidence. There is no modern trial of sermorelin for body composition, recovery or ageing in the indexed literature. Reviews written for orthopaedic audiences group it with the other growth hormone secretagogues on mechanism, while noting that the class activates IGF-1 signalling without established musculoskeletal outcome data ¹³.

The analytical literature — now the bulk of the file. Methods for detecting sermorelin and its metabolites in urine have been developed using nano-liquid chromatography with high-resolution tandem mass spectrometry ^8,12, cation-exchange solid-phase extraction with triple-quadrupole UHPLC-MS/MS ¹⁰, and capillary electrophoresis capable of separating sermorelin from its enantiomeric analogue CJC-1293, which differs by the chirality of a single amino acid ¹¹. In vitro metabolism has been mapped for sermorelin alongside tesamorelin and both CJC-1295 forms ⁶.

Six of the most recent papers carrying this compound’s name are about catching it, not using it — the same pattern seen with TB-500, and for the same reason.

A screening signal in glioma. High-throughput screening identified recurrent glioma as sensitive to sermorelin in silico, with subtype specificity by IDH and 1p/19q status ⁷.

Hypothesis-generating only, and unreplicated.

05 · Evidence overview

06 · Safety profile

Approval-era data. Sermorelin carried two FDA approvals, including one in children dosed daily for extended periods ¹⁷. A paediatric approval requires a safety database in a vulnerable population assessed over the duration of treatment, and the compound cleared that standard. The 2008 withdrawal was explicitly a business decision related to discontinued manufacture of the active ingredient, not a safety action ¹⁷.

Class liability. As with every GHRH analogue, raising growth hormone antagonises insulin action, and effects on glucose tolerance are intrinsic to the mechanism rather than incidental. Reviews of growth hormone secretagogues discuss this as the principal metabolic consideration for the class ^5,14.

What is genuinely unknown. Everything outside the two approved uses. There is no modern safety dataset for sermorelin in adults without growth hormone deficiency, at any dose, over any duration. There is no published data on repeated administration in healthy adults for body composition, which is the way the compound is now discussed. Long-term consequences of sustained GH–IGF1 axis stimulation in people with a normal axis have not been characterised for this compound. And because the product was withdrawn in 2008 ¹⁷, there has been no pharmacovigilance stream on an approved preparation for eighteen years — any material carrying the name now sits outside the quality system that generated the original safety record.

07 · US regulatory status

Current as of 6 September 2026. Sermorelin holds no current US marketing authorisation. It is not a controlled substance.

Its approval history is documented in FDA regulatory records: sermorelin acetate was approved as a diagnostic agent for adult growth hormone deficiency in the early 1990s at 1 µg/kg as a single intravenous injection, marketed as Geref Diagnostic; and for short stature associated with paediatric growth hormone deficiency in the late 1990s at 30 µg/kg/day subcutaneously, marketed as Geref Pediatric under NDA 020443 ¹⁷. The product was withdrawn from marketing in the United States in 2008 following a business decision by the manufacturer, after the active ingredient ceased to be produced ¹⁷.

Sermorelin does not appear in FDA’s category 2 bulk drug substances tables and was not among the substances reviewed by FDA’s Pharmacy Compounding Advisory Committee in July 2026.

Under the World Anti-Doping Code, growth hormone-releasing factors and their analogues are prohibited at all times, and validated urine detection methods for sermorelin and its metabolites have been published ^8,10,12. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The evidence supports two indications, neither of which is how the compound is now used. Diagnosis of growth hormone deficiency and treatment of short stature in growth hormone-deficient children ¹⁷ are the approved uses. Body composition, recovery and ageing in adults with a normal axis have no supporting trial in the indexed literature.

1. The clinical literature effectively stops in 2000. Publication volume is concentrated in the 1980s and 1990s, and the modern record is dominated by analytical chemistry ^{6,8,9,10,11,12}. Twenty-six years of methodological improvement in trial design has not been applied to this compound.

1. The paediatric evidence does not transfer. Efficacy in children with documented growth hormone deficiency measures height velocity in a population with a demonstrable deficit. Neither the endpoint nor the population resembles an adult with a normal GH–IGF1 axis.

1. The pulsatility argument is physiological, not clinical. Preserving pulsatile secretion is a sound rationale for preferring a GHRH analogue over exogenous growth hormone ⁴, and no trial has demonstrated that it produces better outcomes in any population.

1. Withdrawal removed the quality system, not the evidence. The 2008 withdrawal was commercial ¹⁷, so the efficacy data stand — but there has been no approved product, and therefore no manufacturing oversight or pharmacovigilance, for eighteen years.

1. The glioma signal is computational. A high-throughput screening result in tumour datasets ⁷ is a hypothesis about sensitivity, generated in silico, with no treatment study behind it.

1. Modern reviews describe use, not evidence. Where sermorelin appears in recent literature on body composition and performance ^5,15,16, the papers characterise what people are doing. None reports a trial.

09 · References

1. Grossman A, Savage MO, Besser GM. Growth hormone releasing hormone. Clin Endocrinol Metab. 1986;15(3):607–627.

   PMID 2429796 ↗

2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157.

   PMID 18031173 ↗

3. Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279–1291.

   PMID 14499707 ↗

4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308.

   PMID 18046908 ↗

5. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159.

   PMID 32257855 ↗

6. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11–12):1871–1887.

   PMID 34665524 ↗

7. Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021;9(5):406.

   PMID 33842627 ↗

8. Coppieters G, Deventer K, Polet M, Van Eenoo P, Judák P. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. J Pharm Biomed Anal. 2022;214:114726.

   PMID 35298973 ↗

9. González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, et al. In-house standards derived from doping peptides: enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomed Chromatogr. 2023;37(12):e5741.

   PMID 37688464 ↗

10. Cristea CD, Radu M, Toboc A, Stan C, David V. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Anal Biochem. 2023;682:115336.

    PMID 37806509 ↗

11. Otin J, Tran NT, Benoit A, Buisson C, Taverna M. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis. Electrophoresis. 2023;44(9–10):807–817.

    PMID 36787346 ↗

12. Uçaktürk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal. 2026;268:117207.

    PMID 41138283 ↗

13. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

14. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935.

    PMID 41966639 ↗

15. Coutinho LFD, de Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(7):880–885.

    PMID 41880199 ↗

16. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.

    PMID 42395176 ↗

17. US Food and Drug Administration. Regulatory record of sermorelin acetate (Geref Diagnostic; Geref Pediatric, NDA 020443), including approval history and 2008 market withdrawal, as summarised in FDA medical review documentation. Regulatory document; no PMID.

    Source ↗